Skip to main content

Table 5 Cumulative percentages of children with recrudescent infections during follow-up in the two treatment groups

From: Paracetamol versus placebo in treatment of non-severe malaria in children in Guinea-Bissau: a randomized controlled trial

  Paracetamol Placebo OR with confidence interval* OR with confidence interval**
ETF 1.2% (2/167) 4.1% (7/171) 0.28 (0.03 - 1.53)  
Day 4 - 7 4.3% (6/161) 9.5% (9/161) 0.49 (0.18 - 1.24) 0.88 (0.25 - 2.86)
Day 8 - 14 12.2% (12/144) 12.1% (4/135) 0.98 (0.49 - 1.95) 1.36 (0.62 - 3.08)
Day 15 -21 16.6% (6/121) 14.3% (3/120) 1.12 (0.60 - 2.07) 1.49 (0.74 - 3.04)
Day 22 - 28 17.4% (1/109) 14.3% (0/111) 1.16 (0.63 - 2.15) 1.55 (0.78 - 3.16)
Day 29 - 35 17.4% (0/97) 14.3% (0/103) 1.16 (0.63 - 2.15) 1.55 (0.78 - 3.16)
  1. Cumulative percentages of children with recrudescent infections during follow-up. The number of children with recrudescent infections/total number of children is given in parenthesis.
  2. *) The OR (with confidence intervals in brackets) of having recrudescent infections in the paracetamol group as compared to the placebo group when recrudescent infections are defined as PCR-proven recrudescent infections plus ETF.
  3. **) The OR (with confidence intervals in brackets) of having recrudescent infections in the paracetamol group as compared to the placebo group when recrudescent infections are defined as PCR-proven recrudescent infections.